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Introduction: Aldosterone mediates sodium and water retention 
in hypovolemia. In normovolemia, aldosterone primarily mediates 
kaliuresis. To mediate kaliuresis, aldosterone downregulates the 
sodium chloride cotransporters NCC and up-regulates the epithe-
lial sodium channel ENaC. NCC downregulation increases sodium 
chloride transport to ENaC, where it is reabsorbed in turn for potas-
sium, which is then excreted. We investigated whether kaliuresis is 
associated with the aldosterone receptor polymorphism rs3857080 
in normovolemic healthy volunteers.
Patients (or Materials) and Methods: We genotyped 195 healthy 
young men for rs3858070. In a triple-crossover study, 101 of them 
had ingested a sodium-chloride restricted diet 3 times for each a diet 
run-in day, a second diet day and a third diet plus verum day. Verums 
were 25-mg hydrochlorothiazide (HCT), 100-mg HCT and 200-mg 
triamterene. In a second triple-crossover study, 94 men took single 
oral doses of bumetanide (2 mg), furosemide (80 mg), and torsemide 
(10 mg). To avoid hypovolemia, the subjects were repetitively encour-
aged to drink in both studies.
Results: Potassium excretion was in both studies associated 
with rs3857080, which had a minor allele frequency of 0.111. 
Comparatively high potassium excretion was associated with the 
minor A-allele under most conditions (Table). After torsemide, which 
is a loop diuretic such as bumetanide and furosemide but in addi-
tion blocks the aldosterone receptor, potassium excretion was similar 
between the A- and the G-allele of rs3857080.
Table.  Urinary potassium excretion over 24 hours and  
rs3857080.
A/A G/G
NaCl restriction 3.7 (0.2)* 2.8 (0.1)
HCT 25 mg 4.8 (0.6) 3.7 (0.1)
HCT 100 mg 5.5 (0.6) 4.1 (0.1)
Triamterene 3.3 (0.5) 2.2 (0.1)
Bumetanide 3.5 (0.3) 2.8 (0.1)
Furosemide 3.5 (0.3) 3.1 (0.1)
Torsemide 2.5 (0.3) 2.6 (0.1)
*Mean (SEM) of gram amounts normalized to 120 mL/min creatinine clearance.
Conclusion: Taken together, our findings indicate that the A-allele 
of rs3857080 marks a comparatively active aldosterone recep-
tor. Carriers of the A-allele may be prone to hypokalemia and its 
devastating consequences. The A-allele of rs3857080 may predict 
less optimal outcome of diuretic therapy and of heart diseases. 
Antialdosteronergic drugs such as spironolactone, eplerenone, and 
torsemide may be especially indicated in carriers of the A-allele. In 
consequence, rs3857080 is a highly promising candidate for in vitro 
studies as well as for clinical research.
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Introduction: Despite plentiful sunshine in the Middle East, popu-
lations in general, and in Lebanon in particular, have some of the 
lowest levels of 25-hydroxy vitamin D (25-OHD) worldwide. Our 
group has demonstrated such findings across the lifespan; predic-
tors include gender, season, and clothing style (http://staff.aub.edu.
lb/~webcmop/publications.html). However, the possibility of an 
underlying genetic modulation of circulating 25-OHD levels remains 
unexplored. 25-Hydroxylation is mainly driven by cytochrome P-450 
2R1 (CYP2R1) drug metabolizing enzyme; we therefore hypothesized 
that carriage of CYP2R1 single nucleotide polymorphisms (SNPs) 
may be associated with variability in 25-OHD levels.
Patients (or Materials) and Methods: Baseline 25-OHD levels were 
obtained for 172 elderly Lebanese patients: 60% female; age, 70.9 
(4.3) (mean [SD]) years; BMI, 30.3 (4.8) kg/m2; with vitamin D, 
25-OHD, 18.7 (7.9) ng/mL. Genotyping was performed for 4 func-
tionally important SNPs (rs12794714, rs10741657, rs1562902, and 
rs10766197) in CYP2R1 gene by using real-time PCR. Means were 
first compared with univariate analysis, and then multivariate regres-
sion analysis was run adjusting for age, gender, BMI, and season.
Results: Minor allele frequencies were 0.50, 0.29, 0.36, and 0.49 for 
rs12794714, rs10741657, rs1562902, and rs10766197, respectively; 
proportions comparable to those reported in Caucasian popula-
tions. Univariate analysis showed that carriers of the rs12794714 and 
rs10766197 variant alleles are associated with baseline 25-OHD that was 
3.24 ng/mL and 4.48 ng/mL lower, respectively (P = 0.018 and 0.004). 
This significant association remained for rs10766197 after adjusting for 
covariates (β = –6.401 [95% CI, –11.775 to –1.027]; P = 0.020).
Conclusion: This is the first study that shows the association of 
genetic polymorphisms in CYP2R1 with hypovitaminosis D in the 
Middle East. Further analysis is ongoing to evaluate the effect of 
these SNPs on 25-OHD levels achieved after supplementation with 
different doses of vitamin D.
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Introduction: Mirtazapine is a noradrenergic and serotonergic anti-
depressant mainly acting through blockade of presynaptic alpha-2 
receptors. Published data on pregnancy outcome after exposure to 
mirtazapine are scarce. This study addresses the risk associated with 
exposure to mirtazapine during pregnancy.
Patients (or Materials) and Methods: Multicenter (n = 11), observa-
tional prospective cohort study comparing pregnancy outcomes after 
exposure to mirtazapine with 2 matched control groups: exposure 
to any selective serotonin reuptake inhibitor (SSRI) as a disease-
matched control group, and general controls with no exposure to 
medication known to be teratogenic or to any antidepressant. Data 
were collected by members of the European Network of Teratology 
Information Services (ENTIS) during individual risk counseling 
between 1995 and 2011. Standardized procedures for data collec-
tion were used in each center.
Results: A total of 357 pregnant women exposed to mirtazapine 
at any time during pregnancy were included in the study and com-
pared with 357 pregnancies from each control group. The rate of 
major birth defects between the mirtazapine and the SSRI group 
did not differ significantly (4.5% vs 4.2%; unadjusted odds ratio, 
1.1; 95% confidence interval, 0.5–2.3, P = 0.9). A trend toward a 
higher rate of birth defects in the mirtazapine group compared with 
general controls did not reach statistical significance (4.2% vs 1.9%; 
OR, 2.4; 95% CI, 0.9–6.3; P = 0.08). The crude rate of spontane-
ous abortions did not differ significantly between the mirtazapine, 
the SSRI, and the general control groups (9.5% vs 10.4% vs 8.4%; 
P = 0.67), neither did the rate of deliveries resulting in live births 
(79.6% vs 84.3% in both control groups; P = 0.15). However, a 
higher rate of elective pregnancy-termination was observed in the 
mirtazapine group compared with SSRI and general controls (7.8% 
vs 3.4% vs 5.6%; P = 0.03). Premature birth (< 37 weeks) (10.6% 
vs 10.1% vs 7.5%; P = 0.38), gestational age at birth (median, 39 
weeks; interquartile range (IQR), 38–40 in all groups; P = 0.29), 
and birth weight (median, 3320 g; IQR, 2979–3636 vs 3230 g; IQR, 
2910–3629 vs 3338 g; IQR, 2967–3650; P = 0.34) did not differ 
significantly between the groups.
Conclusion: This study did not observe a statistically significant 
difference in the rate of major birth defects between mirtazapine, 
SSRI-exposed, and nonexposed pregnancies. A slightly higher rate 
of birth defects was, however, observed in the mirtazapine and SSRI 
groups compared with the low rate of birth defects in our general 
controls. Overall, the pregnancy outcome after mirtazapine exposure 
in this study is very similar to that of the SSRI-exposed control group.
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Introduction: Spontaneous abortions are the most common com-
plication of pregnancy and nonsteroidal anti-inflammatory drugs 
(NSAID) are among the most widely used groups of drugs during the 
first trimester of pregnancy. Published data are inconsistent regarding 
the risk for spontaneous abortions after exposure to NSAID.
Patients (or Materials) and Methods: A population-based retrospec-
tive cohort study was conducted including all women who conceived 
between January 2003 and December 2009 and admitted for birth 
or diagnosed with spontaneous abortion at Soroka Medical Center, 
Clalit Health Services, Israel. A computerized database of medica-
tion dispension was linked with 2 computerized databases contain-
ing information on births and spontaneous abortions. Time-varying 
COX regression models were constructed adjusting for mother’s age, 
diabetes mellitus, hypothyroidism, hypercoagulable or inflammatory 
conditions, history of recurrent miscarriages, presence of intrauterine 
contraceptive device, ethnicity, and self-reporting tobacco use during 
pregnancy and the year of pregnancy.
Results: There were 65,457 women who conceived during the study 
period and admitted at SMC: 58,949 (90.1%) for birth and 6508 
(9.9%) for spontaneous abortion. A total of 4495 (6.9%) pregnant 
women were exposed to NSAID during the study period. Exposure 
to NSAID was not an independent risk factor for spontaneous abor-
tion as groups (adjusted hazard ratio [HR], 1.08; 95% confidence 
interval [CI], 0.97–1.20 and adjusted HR, 1.67; 95% CI 0.95–2.95 
for nonselective and selective COX2 inhibitors, respectively) or as 
specific drugs. Additionally, no dose response effect was found.
Conclusion: In this large population-based retrospective cohort 
study, no increased risk for spontaneous abortions was found fol-
lowing exposure to NSAID Table. 
Table.  The unadjusted and adjusted risk (hazard ratios and 
95% CI) for spontaneous abortion following exposure 
to NSAID: results from time-varying multivariate Cox 
regression models.
Spontaneous Abortions  
Hazard ratio (95% Ci)
unadjusted Adjusted*
Nonselective COX inhibitors 1.13 (1.01–1.25) 1.08 (0.97–1.20)
Ibuprofen 1.13 (0.98–1.30) 1.05 (0.92–1.21)
Diclofenac 1.21 (0.98–1.48) 1.19 (0.97–1.47)
Indomethacin 3.54 (2.20–5.71) 3.33 (2.06–5.36)
Naproxen 1.87 (0.66–1.17) 0.88 (0.66–1.18)
Etodolac 1.26 (0.88 –1.80) 0.14 (0.8–1.64)
COX2 selective inhibitors 1.97 (1.12–3.47) 1.67 (0.95–2.95)
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Introduction: The pharmaceutical aspects of drug administration in 
clinical trials receive poor consideration compared with the impor-
tant attention devoted to the analytical and mathematical aspects 
